The Beauty Industry is Worth $667 Billion, and Venture Capital Arrived Late
Cosmoprof Worldwide Bologna, the leading fair in the global cosmetics sector, concluded its 57th edition with a sign that would have seemed improbable a decade ago: venture capital funds competing for space in the aisles alongside active formulators and packaging distributors. Artificial intelligence, biotechnology, and institutional money have converged on an industry that moves $667 billion annually and that, for decades, operated in silence while speculative capital pursued software, mobility, and cryptocurrencies.
This figure deserves a moment’s consideration. Six hundred sixty-seven billion dollars is more than double the global video game market. It is an industry that survived the pandemic, inflation, and multiple regional recessions, with a demand that economists label inelastic, which operationally means something more precise: people stop buying cars before they stop buying sunscreen or lipstick. Yet, institutional capital took decades to take it seriously.
Why Smart Money Ignored a Business That Never Stopped Growing
The answer has more to do with structural biases than market fundamentals. Traditional venture capital built its return theses on technology scalability models: software with near-zero marginal costs, platforms with network effects, digital infrastructure that replicates frictionlessly. Beauty, with its physical supply chain, its formulation cycles, its market-specific regulations, and its dependence on sensory perception, didn’t fit that mental model.
The error in this reading was to confuse operational complexity with a lack of scalability. Direct-to-consumer beauty brands demonstrated over the last decade that sector gross margins can exceed 70%, comparable to many software firms. The difference is that, unlike an app that can be copied in weeks, a formulation with proprietary biotech assets or a brand with accumulated cultural capital takes years to replicate. That is not a competitive weakness; it is the most enduring form of defensive moat that exists.
What changed in this cycle is not the industry. It changed the capacity of funds to read its metrics. The convergence of AI and biotechnology in the formulation chain has drastically reduced product development times, one of the historical bottlenecks of the sector. A startup that previously needed between 18 and 24 months to bring an asset from the lab to retail can now compress that cycle to less than a year using predictive dermal efficacy models. This transforms a business that seemed to have slow cycles into one with iteration speeds comparable to software.
When Biotechnology Changes the Unit Economics of the Product
Here lies the core of the structural change that Cosmoprof made visible this year: biotechnology not only improves the product, it completely reorganizes its cost architecture. An internally developed biotech asset can have a decreasing marginal production cost as it scales, exactly the profile that venture capital valuation models reward. The difference with the previous investment cycle in beauty, which focused on high customer acquisition spending DTC brands, is fundamental.
The DTC brands of the first wave burned capital in paid channels on Meta and Google building audiences that never belonged to them. Their unit economics depended on maintaining artificially low customer acquisition costs in an advertising environment that inevitably became more expensive. When the cost per click rose and Apple modified its privacy policies, the model collapsed. Several brands that reached nine-figure valuations between 2018 and 2021 shut down or were sold at liquidation prices.
The startups that are now attracting smart capital in the sector have a different architecture. Their competitive advantage lies in formulation and intellectual property, not in marketing budgets. This means their variable costs scale predictably with volume, and their margin does not depend on an advertising algorithm they do not control. For an investor who learned the lessons from the first DTC wave, that distinction is not minor: it is the difference between financing a business and financing a disguised advertising arbitrage.
From my analytical perspective, there is one variable that headlines about this boom consistently overlook: the distribution of value along the chain. A cosmetic biotech startup with solid intellectual property can capture margin in formulation, branding, and the clinical data supporting its claims. That is stacked value at multiple levels. However, if that same startup relies on outsourced manufacturing concentrated among few global suppliers, and on distribution controlled by large retailers, its negotiating power erodes exactly at the two ends where margin is most sensitive.
The capital now entering the sector has an obligation to audit that chain with the same rigor it would audit the code of a software company. A brand selling dermal wellness while its chain of active ingredients relies on unverified labor conditions at origin does not have an abstract ethical problem: it has a concrete operational risk that sooner or later materializes in a reputation crisis or a supply disruption.
The Capital Coming Now Must Not Repeat Past Mistakes
Beauty, as a category for institutional investment, does not need validation. Its numbers validate it on their own. What it needs is capital with more sophisticated evaluation criteria than those that dominated the previous cycle, when the dominant metric was quarter-over-quarter revenue growth, regardless of customer acquisition costs or retention profiles.
The sector startups that will endure are those that understand their business model must generate cash before needing the next round. This means charging upfront wherever possible, building direct relationships with consumers that do not depend on costly digital intermediaries, and anchoring their differentiation in assets that cannot be replicated on a bigger budget. AI and biotechnology are tools to reduce the time and cost of building those assets, not substitutes for financial discipline.
The venture capital arriving at Cosmoprof with novel theses faces a mature, profitable industry with solid structural demand. The question that each fund should answer before signing a term sheet is not whether the category has a future, but whether the specific model they are financing generates value for all actors in its chain, or if it is simply shifting risk to suppliers and workers to protect shareholder margins.
The leaders of the startups now receiving this capital face a choice that defines the durability of what they are building. They can use that money as fuel to elevate the conditions of their supply chain, invest in intellectual property that provides them real autonomy, and build models where the consumer and the supplier share in the growth. Or they can use it to buy short-term growth in channels they do not control, leaving the chain to absorb the pressure. The first path builds a business that is worth more with each cycle. The second builds one that depends on the next check to survive.
